Skip to content

Investigating the effect of Bupivacaine on post operative pain after rhinoplasty

Investigating the effect of injectable and topical Bupivacaine on post operative pain after rhinoplasty

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20131020015083N5
Enrollment
50
Registered
2024-02-07
Start date
2024-02-20
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients underwent rhinoplasty. Encounter for plastic and reconstructive surgery following medical procedure or healed injury

Interventions

Intervention 1: patients who at the end of the operation (before the patient regains consciousness) will be injected with bupivacaine (Marcaine® 0.5%: Aspen Japan
Tokyo, Japan) with a total volume of 4 ml as a local anesthetic. Intervention 2: Intervention group:There are patients who will be administered local anesthetic bupivacaine (Marcaine® 0.5%: Aspen Japa
Tokyo, Japan) with a total volume of 4 ml at the beginning of the procedure. Intervention 3: Intervention group: There are patients who receive local bupivacaine through the mesh (each mesh 1 cc, 2 cc

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 50 Years

Inclusion criteria

Inclusion criteria: ASA I physical status based on the American Classification of Anesthesiology (ASA) Age between 17 and 50 years Performing primary rhinoplasty with standard technique and oblique lateral-medial osteotomy

Exclusion criteria

Exclusion criteria: Not agreeing to participate in the study Patients with cardiovascular disease History of sensitivity to bupivacaine Receiving other anesthetics before and during the operation Cognitive disorders and the inability to communicate and express the level of pain

Design outcomes

Primary

MeasureTime frame
Degree of nasal pain. Timepoint: 1 hour after the operation, 6 hours after the operation, 1 day after the operation, 2 days after the operation and 3 days after the operation. Method of measurement: Visual analog scale (VAS).;Analgesic consumption. Timepoint: 1 hour after the operation, 6 hours after the operation, 1 day after the operation, 2 days after the operation and 3 days after the operation. Method of measurement: Asking the patient directly and recording analgesic consumption.

Secondary

MeasureTime frame
Nausea-vomiting. Timepoint: 1 hour after the operation, 6 hours after the operation, 1 day after the operation, 2 days after the operation and 3 days after the operation. Method of measurement: Visual analog scale.;Postoperative complications. Timepoint: up to 7 days. Method of measurement: direct physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Reza Kaboodkhani

Shiraz University of Medical Sciences

kaboodkhani@yahoo.com+98 71 3629 1470

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026